368 related articles for article (PubMed ID: 26554630)
1. Tolerability, Safety, and Quality of Life with Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR in Patients with Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-label, Phase 3b/4 Trial.
Baron R; Jansen JP; Binder A; Pombo-Suarez M; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):600-19. PubMed ID: 26554630
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of Tapentadol Prolonged Release (PR) Compared with Oxycodone/Naloxone PR for the Management of Severe Chronic Low Back Pain with a Neuropathic Component: A Randomized, Controlled, Open-Label, Phase 3b/4 Study.
Baron R; Likar R; Martin-Mola E; Blanco FJ; Kennes L; Müller M; Falke D; Steigerwald I
Pain Pract; 2016 Jun; 16(5):580-99. PubMed ID: 26095455
[TBL] [Abstract][Full Text] [Related]
3. Tapentadol prolonged release versus strong opioids for severe, chronic low back pain: results of an open-label, phase 3b study.
Gálvez R; Schäfer M; Hans G; Falke D; Steigerwald I
Adv Ther; 2013 Mar; 30(3):229-59. PubMed ID: 23475406
[TBL] [Abstract][Full Text] [Related]
4. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain.
Vondrackova D; Leyendecker P; Meissner W; Hopp M; Szombati I; Hermanns K; Ruckes C; Weber S; Grothe B; Fleischer W; Reimer K
J Pain; 2008 Dec; 9(12):1144-54. PubMed ID: 18708300
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and Tolerability of a Moderate Dose of Tapentadol Prolonged Release for Managing Severe, Chronic Low Back Pain with a Neuropathic Component: An Open-label Continuation Arm of a Randomized Phase 3b Study.
Baron R; Kern U; Müller M; Dubois C; Falke D; Steigerwald I
Pain Pract; 2015 Jun; 15(5):471-86. PubMed ID: 24750558
[TBL] [Abstract][Full Text] [Related]
6. Impact of prolonged-release oxycodone/naloxone on outcomes affecting patients' daily functioning in comparison with extended-release tapentadol: a systematic review.
Thakur D; Dickerson S; Kumar Bhutani M; Junor R
Clin Ther; 2015 Jan; 37(1):212-24. PubMed ID: 25592091
[TBL] [Abstract][Full Text] [Related]
7. [Tapentadol prolonged release improves analgesia, functional impairment and quality of life in patients with chronic pain who have previously received oxycodone/naloxone].
Kern KU; Krings D; Waldmann-Rex S
MMW Fortschr Med; 2014 Jul; 156 Suppl 2():54-63. PubMed ID: 25351028
[TBL] [Abstract][Full Text] [Related]
8. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and safety of tapentadol prolonged release for severe, chronic low back pain with or without a neuropathic pain component: results of an open-label, phase 3b study.
Steigerwald I; Müller M; Davies A; Samper D; Sabatowski R; Baron R; Rozenberg S; Szczepanska-Szerej A; Gatti A; Kress HG
Curr Med Res Opin; 2012 Jun; 28(6):911-36. PubMed ID: 22443293
[TBL] [Abstract][Full Text] [Related]
10. Prolonged-release oxycodone/naloxone in the treatment of neuropathic pain - results from a large observational study.
Hermanns K; Junker U; Nolte T
Expert Opin Pharmacother; 2012 Feb; 13(3):299-311. PubMed ID: 22224497
[TBL] [Abstract][Full Text] [Related]
11. Combatting pain after orthopedic/trauma surgery- perioperative oral extended-release tapentadol vs. extended-release oxycodone/naloxone.
Haeseler G; Schaefers D; Prison N; Ahrens J; Liu X; Karch A
BMC Anesthesiol; 2017 Jul; 17(1):91. PubMed ID: 28693439
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and Safety of Tapentadol Prolonged Release (PR) Versus a Combination of Tapentadol PR and Pregabalin for the Management of Severe, Chronic Low Back Pain With a Neuropathic Component: A Randomized, Double-blind, Phase 3b Study.
Baron R; Martin-Mola E; Müller M; Dubois C; Falke D; Steigerwald I
Pain Pract; 2015 Jun; 15(5):455-70. PubMed ID: 24738609
[TBL] [Abstract][Full Text] [Related]
13. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain.
Simpson K; Leyendecker P; Hopp M; Müller-Lissner S; Löwenstein O; De Andrés J; Troy Ferrarons J; Bosse B; Krain B; Nichols T; Kremers W; Reimer K
Curr Med Res Opin; 2008 Dec; 24(12):3503-12. PubMed ID: 19032132
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of combined prolonged-release oxycodone and naloxone in the management of non-cancer chronic pain.
Sandner-Kiesling A; Leyendecker P; Hopp M; Tarau L; Lejcko J; Meissner W; Sevcik P; Hakl M; Hrib R; Uhl R; Dürr H; Reimer K
Int J Clin Pract; 2010 May; 64(6):763-74. PubMed ID: 20370845
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of tapentadol prolonged release for moderate-to-severe chronic osteoarthritis knee pain: a pooled analysis of two double-blind, randomized, placebo- and oxycodone controlled release-controlled studies.
Lange B; von Zabern D; Elling C; Dubois C
Curr Med Res Opin; 2017 Aug; 33(8):1413-1422. PubMed ID: 28537506
[TBL] [Abstract][Full Text] [Related]
17. A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone-naloxone (up to 160/80 mg daily) vs oxycodone PR.
Dupoiron D; Stachowiak A; Loewenstein O; Ellery A; Kremers W; Bosse B; Hopp M
Eur J Pain; 2017 Oct; 21(9):1528-1537. PubMed ID: 28641363
[TBL] [Abstract][Full Text] [Related]
18. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial.
Löwenstein O; Leyendecker P; Hopp M; Schutter U; Rogers PD; Uhl R; Bond S; Kremers W; Nichols T; Krain B; Reimer K
Expert Opin Pharmacother; 2009 Mar; 10(4):531-43. PubMed ID: 19243306
[TBL] [Abstract][Full Text] [Related]
19. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation.
Meissner W; Leyendecker P; Mueller-Lissner S; Nadstawek J; Hopp M; Ruckes C; Wirz S; Fleischer W; Reimer K
Eur J Pain; 2009 Jan; 13(1):56-64. PubMed ID: 18762438
[TBL] [Abstract][Full Text] [Related]
20. Prolonged-Release Oxycodone/Naloxone Improves Anal Sphincter Relaxation Compared to Oxycodone Plus Macrogol 3350.
Poulsen JL; Brock C; Grønlund D; Liao D; Gregersen H; Krogh K; Drewes AM
Dig Dis Sci; 2017 Nov; 62(11):3156-3166. PubMed ID: 28986667
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
